Stockscreener 앱 받기
1.29
1.57%
0.02
시간 외 거래:
1.28
-0.01
-0.78%
전일 마감가:
$1.27
열려 있는:
$1.3
하루 거래량:
367.75K
Relative Volume:
0.86
시가총액:
$34.29M
수익:
$50,000
순이익/손실:
$-45.93M
주가수익비율:
-0.6704
EPS:
-1.9241
순현금흐름:
$-23.62M
1주 성능:
+4.88%
1개월 성능:
-3.01%
6개월 성능:
-35.82%
1년 성능:
-81.14%
1일 변동 폭
$1.265
$1.32
1주일 범위
$1.18
$1.32
52주 변동 폭
$1.09
$11.64
Inmune Bio Inc Stock (INMB) Company Profile
명칭
Inmune Bio Inc
전화
(858) 964-3720
주소
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
1.29 | 33.76M | 50,000 | -45.93M | -23.62M | -1.9241 |
VRTX
Vertex Pharmaceuticals Inc
|
443.92 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
775.53 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
785.07 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
327.25 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.19 | 33.72B | 5.36B | 287.73M | 924.18M | 2.5229 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-01 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-07-01 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Underperform |
| 2025-01-28 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-21 | 개시 | Alliance Global Partners | Buy |
| 2024-09-27 | 개시 | Raymond James | Outperform |
| 2024-08-22 | 개시 | Scotiabank | Sector Outperform |
| 2023-06-01 | 개시 | Robert W. Baird | Outperform |
| 2022-05-24 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-07-07 | 재확인 | Maxim Group | Buy |
| 2021-04-21 | 개시 | B. Riley Securities | Buy |
| 2021-01-22 | 재확인 | Maxim Group | Buy |
| 2020-09-01 | 개시 | BTIG Research | Buy |
| 2020-07-15 | 재확인 | H.C. Wainwright | Buy |
모두보기
Inmune Bio Inc 주식(INMB)의 최신 뉴스
INMune Bio, Inc. (NASDAQ:INMB) Q4 2025 earnings call transcript - MSN
INmune Bio (INMB) price target increased by 33.33% to 7.14 - msn.com
Support Test: Whats the RSI of INmune Bio Inc stockWeekly Investment Report & Capital Efficiency Focused Strategies - baoquankhu1.vn
INMB.O PE Ratio & Valuation, Is INMB.O Overvalued - Intellectia AI
INmune Bio, Inc. (NASDAQ:INMB) Q4 2025 Earnings Call Transcript - Insider Monkey
INmune Bio (NASDAQ:INMB) Will Have To Spend Its Cash Wisely - Yahoo Finance
S P Trends: Whats the profit margin of INmune Bio IncWeekly Trade Report & Weekly Stock Performance Updates - baoquankhu1.vn
INmune Bio, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Earnings Call Summary | INmune Bio(INMB.US) Q4 2025 Earnings Conference - Moomoo
Inmune Bio Inc Stock: Recent 2025 Results Highlight Late-Stage Pipeline Progress Amid Cash Runway to - AD HOC NEWS
INmune Bio reports $45.9M loss, plans UK regulatory filing By Investing.com - Investing.com South Africa
INmune Bio Inc (INMB) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
INmune Bio Q4 2025 Earnings Call Transcript - MarketBeat
INmune Bio Inc (INMB) Q4 2025 Earnings Call Highlights: Strategi - GuruFocus
INmune Bio Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Earnings call transcript: INmune Bio highlights CORDStrom progress in Q4 2025 - Investing.com Canada
INmune Bio | 10-K: FY2025 Annual Report - Moomoo
INMB: CORDStrom nears regulatory filings as cash runway extends to Q1 2027 after $27.5M raised - TradingView
Pipeline reset at INmune Bio (NASDAQ: INMB) after CORDStrom gains and XPro setback - Stock Titan
INmune Bio reports $45.9M loss, plans UK regulatory filing - Investing.com
INmune Bio Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Short Squeeze: Will INmune Bio Inc outperform tech stocksTrade Performance Summary & Fast Gain Stock Tips - baoquankhu1.vn
INMune Bio FY 2025 earnings preview - MSN
INmune Bio Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
INmune Bio Inc expected to post a loss of 26 cents a shareEarnings Preview - TradingView
INMB Technical Analysis | Trend, Signals & Chart Patterns | INMUNE BIO INC (NASDAQ:INMB) - ChartMill
INmune Bio (INMB.US) will release its earnings report after the market close on March 30. - Moomoo
INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th. - The Manila Times
INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on ... - Bluefield Daily Telegraph
INmune Bio will discuss 2025 results and corporate update March 30 - stocktitan.net
Market Moves: Whats the RSI of INmune Bio Inc stock2026 Buyback Activity & Low Drawdown Investment Ideas - baoquankhu1.vn
If You Invested $1,000 in Inmune Bio Inc (INMB) - Stock Titan
Block Trades: How does INmune Bio Inc compare to its peersMarket Risk Report & Momentum Based Trading Ideas - baoquankhu1.vn
INMB PE Ratio & Valuation, Is INMB Overvalued - Intellectia AI
INMB Showcases Advancements in Alzheimer's Treatment at AD/PD 20 - GuruFocus
INmune Bio’s MINDFuL trial presented as succesful example in Alzheimer’s - TipRanks
INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease - The Manila Times
Alzheimer’s trial gets plenary spotlight as blood markers guide treatment - Stock Titan
INMB stock rises pre-market – what did the FDA say about its Alzheimer’s trial? - MSN
Rally Mode: Whats the profit margin of INmune Bio IncTrade Exit Report & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Market Outlook: Is INmune Bio Inc stock undervalued right nowPortfolio Risk Summary & Accurate Buy Signal Notifications - baoquankhu1.vn
Setup Watch: How liquid is INmune Bio Inc stockTrade Entry Report & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Will INmune Bio Inc benefit from geopolitical trends2026 Momentum & Free Community Supported Trade Ideas - baoquankhu1.vn
INmune Bio Inc Stock (ISIN: US45764T1060) Faces Analyst Hold Consensus Amid $8 Price Target - AD HOC NEWS
INmune Bio Receives $8 Consensus Price Target from Analysts - National Today
INmune Bio (NASDAQ:INMB) Stock Rating Upgraded by Lucid Cap Mkts - Defense World
Lucid Capital Markets upgrades INmune Bio (INMB) - MSN
INMB Stock Receives Major Upgrade from Lucid Capital Markets | I - GuruFocus
Lucid Capital Markets upgrades INmune Bio stock rating on RDEB therapy - Investing.com Australia
Inmune Bio Inc (INMB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.51%
1.75%
자본화:
|
볼륨(24시간):